Search

Résumé: Les manifestations extra-intestinales des maladies inflammatoires chroniques de l'intestin (MICI) sont fréquentes et polymorphes, dominées par les atteintes ostéoarticulaires et cutanéo-muqueuses. Ces manifestations ont un impact significatif sur la qualité de vie des patients et sur les choix thérapeutiques du clinicien. Les manifestations extra-intestinales associées aux MICI surviennent de façon plus fréquente au cours de la maladie de Crohn par rapport à la rectocolite hémorragique. La plupart des manifestations extradigestives évoluent de façon synchrone avec l'activité de la MICI. Un certain nombre peut néanmoins évoluer de façon dissociée, nécessitant des prises en charge concomitantes. Cette distinction souligne la physiopathologie complexe de ces manifestations qui peuvent faire intervenir d'un côté le déclenchement d'une réponse immunitaire au-delà du tube digestif via une translocation d'épitopes bactériens et de l'autre, une communauté de facteurs génétiques et environnementaux partagés par différentes entités inflammatoires. Dans cette revue, nous aborderons les aspects cliniques des manifestations extra-intestinales et ses conséquences sur la prise en charge des MICI. Patients with Inflammatory Bowel Disease (IBD) experience at least one extra-intestinal manifestation (EIM) in up to 50% of the cases. EIM have a negative impact on the patient's quality of life and may interfere with treatment decision-making. EIMs are more common in CD than UC and there is a broad range of manifestations. The most prevalent EIMs in IBD are arthralgia/arthritis and skin manifestations. Most EIMs run in parallel with the intestinal disease activity but they may also have distinct course requiring multidisciplinary management. The pathogenesis of EIM in IBD is not univocal, combining a trigger immune response at the extraintestinal site due to translocation of bacterial epitopes and a shared community of genetic and environmental factors. This review focuses on the clinical features of EIM and consequences on the management of patients with IBD. [ABSTRACT FROM AUTHOR]

(1) Background: Anastomotic biliary stricture (ABS) is a well-known complication of liver transplantation which can lead to secondary biliary cirrhosis and graft dysfunction. The goal of this study was to evaluate the long-term outcomes of endoscopic metal stenting of ABS in the setting of deceased donor liver transplantation (DDLT). (2) Methods: Consecutive DDLT patients with endoscopic metal stenting for ABS between 2010 and 2015 were screened. Data on diagnosis, treatment and follow-up (until June 2022) were collected. The primary outcome was endoscopic treatment failure defined as the need for surgical refection. (3) Results: Among the 465 patients who underwent LT, 41 developed ABS. It was diagnosed after a mean period of 7.4 months (+/−10.6) following LT. Endoscopic treatment was technically successful in 95.1% of cases. The mean duration of endoscopic treatment was 12.8 months (+/−9.1) and 53.7% of patients completed a 1-year treatment. After a mean follow-up of 6.9 years (+/−2.3), endoscopic treatment failed in nine patients (22%) who required surgical refection. Conclusions: Endoscopic management with metal stenting of ABS after DDLT was technically successful in most cases, and half of the patients had at least one year of indwelling stent. Endoscopic treatment long-term failure rate occurred in one fifth of the patients. [ABSTRACT FROM AUTHOR]